Clinical Trials on Epilepsy Comorbidities in Portugal

Total 41 results

Bial - Portela C S.A.

Completed

Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive

Partial Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures

Refractory Partial Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy

Partial Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy

Partial Epilepsy

Portugal
Bial - Portela C S.A.

Terminated

The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093

Epilepsy

Portugal
Sándor Beniczky
Hospital del Mar; Centro Hospitalar e Universitário de Coimbra, E.P.E.; Motol... and other collaborators

Active, not recruiting

Clinical Utility of Automated Electric Source Imaging in Presurgical Evaluation (PROMAESIS)

Surgery | Refractory Epilepsy | Electroencephalography | Brain Imaging

Spain, Portugal, Austria, Czechia, Denmark, Germany, Italy, Romania
MedtronicNeuro

Completed

Product Surveillance Registry- Deep Brain Stimulation for Epilepsy (MORE)

Refractory Epilepsy

Belgium, Sweden, Austria, United Kingdom, Poland, Germany, Portugal, Canada, Finland, Hungary, Italy, Netherlands, Russian Federation
Universitaire Ziekenhuizen KU Leuven
King's College London; Karolinska Institutet; UCB Pharma; University of Coimbra; RWTH... and other collaborators

Completed

Clinical Scenarios for Long-term Monitoring of Epileptic Seizures With a Wearable Biopotential Technology (SeizeIT2)

Epilepsy

Belgium, Germany, Portugal, Sweden, United Kingdom
Eisai Limited

Completed

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Idiopathic Generalized Epilepsy | Partial Onset Seizures | Generalised Tonic-Clonic Seizures

France, Spain, Italy, Denmark, Germany, Portugal, Russian Federation
MedtronicNeuro

Recruiting

Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS) (EPAS)

Epilepsy

United States, Belgium, Czechia, Portugal
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children

Partial Epilepsy in Children and Adolescents

United Kingdom, Spain, Serbia, Italy, Austria, Bosnia and Herzegovina, Croatia, Czechia, France, Germany, Hungary, Malaysia, Moldova, Republic of, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Taiwan, Ukr...
UCB Biopharma S.P.R.L.

Completed

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy (ARISE)

Focal-Onset Seizures | Drug-resistant Epilepsy

United States, Australia, Belgium, Bulgaria, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Lithuania, Mexico, Poland, Portugal, Slovakia, Spain, Turkey, United Kingdom
UCB Biopharma SRL

Terminated

A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy (DUET)

Drug-Resistant Epilepsy | Focal-Onset Seizures

United States, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerlan... and more
LivaNova

Active, not recruiting

Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System. (CORE-VNS)

Epilepsy | Seizures | Drug Resistant Epilepsy

Australia, Italy, United States, Israel, United Kingdom, Canada, Brazil, Japan, Belgium, India, Austria, China, Netherlands, Poland, Portugal, Saudi Arabia
UCB BIOSCIENCES, Inc.

Completed

Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures

Epilepsy With Partial-onset Seizures

United States, Argentina, Brazil, Bulgaria, China, Croatia, Czechia, France, Georgia, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Moldova, Republic of, Philippines, Poland, Portugal, Romania, Russian Federation, Se... and more
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy

Epilepsy, Partial

Belgium, Finland, Hungary, Korea, Republic of, Spain, Taiwan, China, Mexico, Singapore, Thailand, Germany, Portugal, Hong Kong, Italy, United Kingdom, Sweden, Slovakia, Estonia, France, Netherlands, Latvia, India, Bulgaria, Norway, Czechia and more
Bial - Portela C S.A.

Completed

Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients

Epilepsy

Spain, Bulgaria, Austria, Croatia, Czechia, France, Germany, Poland, Portugal, Romania
GlaxoSmithKline

Completed

Pediatric Epilepsy Trial in Subjects 1-24 Months

Epilepsy

United States, Estonia, Portugal, Slovakia, Netherlands, Hungary, Italy, Lithuania, Australia, France, Spain, Latvia, Lebanon, Turkey
Takeda
Ovid Therapeutics Inc.

Completed

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies (ELEKTRA)

Epilepsy | Dravet Syndrome | Lennox-Gastaut Syndrome

United States, Canada, Israel, Poland, Spain, Australia, China, Portugal
GlaxoSmithKline

Completed

Pediatric Epilepsy Study in Subjects 1-24 Months

Epilepsy

United States, Estonia, Portugal, Slovakia, Netherlands, Hungary, Italy, Argentina, Lithuania, France, Australia, Latvia, Lebanon, Puerto Rico, Turkey
Eisai Inc.

Completed

Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Epilepsy

Belgium, Germany, China, Hong Kong, United States, France, Romania, Mexico, South Africa, India, Portugal, Russian Federation, Italy, Canada, Australia, Taiwan, Austria, Malaysia, Hungary, Poland, Thailand, Sweden, Bulgaria, Serbia, Greece and more
Takeda

Active, not recruiting

A Study of Soticlestat in Adults and Children With Rare Epilepsies (Endymion 1)

Epilepsy | Dravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)

United States, Canada, Australia, China, Israel, Poland, Spain, Portugal
Newcastle University
Assistance Publique - Hôpitaux de Paris; Medical University of Vienna; University... and other collaborators

Recruiting

The European NAFLD Registry

Cardiovascular Diseases | Hypertension | Obesity | Hepatocellular Carcinoma | Type 2 Diabetes | NAFLD | Fibrosis, Liver | NASH - Nonalcoholic Steatohepatitis | Dyslipidaemia | NASH | Steatosis of Liver | Other Associated Comorbidities

Netherlands, Germany, United Kingdom, Finland, Belgium, Greece, Italy, Sweden, Portugal, Spain, France, Switzerland
UCB BIOSCIENCES GmbH
Eden Sarl

Completed

Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older

Epilepsy | Monotherapy

United States, Australia, Belgium, Bulgaria, Canada, Czechia, Finland, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Swede... and more
UCB BIOSCIENCES, Inc.
UCB Biopharma SRL

Completed

A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

Epilepsy

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, China, Colombia, Croatia, Czechia, Estonia, France, Georgia, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Monten... and more
UCB BIOSCIENCES GmbH
Eden Sarl

Completed

Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older (SP0993)

Epilepsy | Monotherapy

United States, Australia, Belgium, Bulgaria, Canada, Czechia, Finland, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Spa... and more
UCB BIOSCIENCES, Inc.

Completed

Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures (VALUE)

Epilepsy

United States, Australia, Brazil, Bulgaria, China, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Taiwan
Pfizer

Completed

Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Seizure Disorder, Partial

Australia, Spain, Portugal, United Kingdom, Canada, Belgium, Germany, Poland, Netherlands, Austria
UCB BIOSCIENCES, Inc.
Pharmaceutical Research Associates

Completed

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications (VALOR)

Epilepsy

United States, Australia, Belgium, Brazil, Bulgaria, China, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Taiwan
SK Life Science, Inc.

Recruiting

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

Seizures | Lennox Gastaut Syndrome

United States, Korea, Republic of, Taiwan, Colombia, Australia, Poland, Serbia, Mexico, Spain, Greece, Italy, Portugal, Germany, Argentina, Israel
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study

Migraine Without Aura | Migraine With Aura

Spain, France, Italy, Netherlands, Turkey, Belgium, Hungary, Czechia, Denmark, Germany, Greece, Norway, Portugal, Sweden

Clinical Trials on Epilepsy Comorbidities in Portugal

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations